ReviewExpert opinion on investigational drugs2010
Newer antibacterial drugs for a new century.
Review in Expert opinion on investigational drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.Critical care (London, England) · 2012Trial
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Ethanolic extracts from deep marine sponges: A new frontier in antibacterial discovery from the Jordanian Gulf of Aqaba.Biomedical reports · 2026Article
- Selective Targeting and Enhanced Photodynamic Inactivation of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Synthesis and biological activity evaluation of a novel pleuromutilin derivative 22-((2-methyl-1-(1H-pyrrole-2-carboxamido)propan-2-yl)thio)-deoxypleuromutilin.Frontiers in pharmacology · 2025Article
- Global research trends in therapeutic drug monitoring of antimicrobials from 2000 to 2023: a bibliometric analysis.Frontiers in pharmacology · 2024Article
- The effect of novel antimicrobial agents on the normal functioning of human intestinal microbiota: a systematic review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Antimicrobial Resistance and Its Drivers-A Review.Antibiotics (Basel, Switzerland) · 2022Review
- Novel Nitro-Heteroaromatic Antimicrobial Agents for the Control and Eradication of Biofilm-Forming Bacteria.Antibiotics (Basel, Switzerland) · 2021Article
- The Distribution and Antibacterial Activity of Marine Sponge-Associated Bacteria in the Aegean Sea and the Sea of Marmara, Turkey.Current microbiology · 2021Article
- Nanozyme Applications: A Glimpse of Insight in Food Safety.Frontiers in bioengineering and biotechnology · 2021Review
- Novel heterocyclic hybrids of pyrazole targeting dihydrofolate reductase: design, biological evaluation andJournal of enzyme inhibition and medicinal chemistry · 2020Article
- Antimicrobial activity of bacteria from marine spongeSaudi journal of biological sciences · 2020Article
- Novel phthalimide based analogues: design, synthesis, biological evaluation, and molecular docking studies.Journal of enzyme inhibition and medicinal chemistry · 2019Article
- Antibacterial activity of 3-methylbenzo[d]thiazol-methylquinolinium derivatives and study of their action mechanism.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Society for Translational Medicine expert consensus on the use of antibacterial drugs in thoracic surgery.Journal of thoracic disease · 2018Review
- Application of Nanoparticle Technologies in the Combat against Anti-Microbial Resistance.Pharmaceutics · 2018Review
- Suppressive drug combinations and their potential to combat antibiotic resistance.The Journal of antibiotics · 2017Review
- New application of tiplaxtinin as an effective FtsZ-targeting chemotype for an antimicrobial study.MedChemComm · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
importance of the fieldAntibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Instead, improved analogues of existing classes of antibacterial drugs have been developed by improving potency, minimizing resistance and alleviating toxicity. AREAS COVERED IN THIS REVIEW: This article is a comprehensive review of newer classes of antibacterial drugs introduced or approved after year 2000. WHAT THE READER WILL GAIN: It describes their mechanisms of action/resistance, improved analogues, spectrum of activity and clinical trials. It also discusses new compounds in development with novel mechanisms of action, as well as novel unexploited bacterial targets and strategies that may pave the way for combating drug resistance and emerging pathogens in the twenty-first century. TAKE HOME MESSAGE: The outlook of antibacterial drug discovery, though challenging, may not be insurmountable in the years ahead, with legislation on incentives and funding introduced for developing an antimicrobial discovery program and efforts to conserve antibacterial drug use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.